HoxB13 Inhibitors
HoxB13 inhibitors encompass a broad spectrum of chemicals that indirectly modulate the activity of the HoxB13 protein by influencing various signaling pathways and cellular processes. These inhibitors do not interact directly with HoxB13 but exert their effects by altering the cellular milieu in which HoxB13 functions. As HoxB13 is implicated in cell differentiation, development, and other cellular processes, the chemicals targeting pathways related to these processes can indirectly impact HoxB13 activity. The inhibitors include a range of compounds like LY294002, which inhibits the PI3K/Akt pathway, critical for cell survival and proliferation. This pathway's modulation can affect HoxB13 activity indirectly by altering cell survival mechanisms. Similarly, Rapamycin, an mTOR inhibitor, and PD98059, a MEK inhibitor, target pathways involved in cell growth and differentiation. Their actions can create a cellular environment that influences HoxB13's function in these processes. SB431542, a TGF-β receptor inhibitor, and U0126, another MEK inhibitor, also exert their effects in a similar manner, targeting crucial signaling pathways in cell differentiation and proliferation.
In addition to these, SP600125 and SB203580, which inhibit the JNK and p38 MAPK pathways respectively, affect cellular stress responses and inflammation. These pathways are intricately connected to the processes governing cellular development, in which HoxB13 is a key player. DAPT's role as a γ-secretase inhibitor affects Notch signaling, pivotal in cell fate decisions, thereby influencing HoxB13's function. Moreover, compounds like Bicalutamide, an androgen receptor antagonist, and Palbociclib, a CDK4/6 inhibitor, demonstrate the diversity of these inhibitors. They interact with hormone signaling and cell cycle progression, respectively, showcasing the interconnectedness of various cellular pathways with HoxB13's role in cell differentiation and development. Furthermore, Vorinostat, an HDAC inhibitor, and Nutlin-3, which stabilizes p53, highlight the influence of gene expression regulation and cell cycle arrest on HoxB13's activity. By modulating chromatin structure and gene expression (Vorinostat) and influencing p53-mediated processes (Nutlin-3), these compounds provide an indirect avenue to inhibit HoxB13.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, LY294002 downregulates the PI3K/Akt pathway, which is crucial for cell survival and proliferation. HoxB13 has been implicated in similar cellular processes, and modulation of the PI3K/Akt pathway could indirectly inhibit HoxB13 activity by affecting cell survival mechanisms. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, specifically binding to mTORC1. The inhibition of mTORC1 by rapamycin disrupts protein synthesis and cell growth. Since HoxB13 is involved in cellular developmental processes, altering mTORC1 activity can indirectly influence HoxB13 by modifying the cellular environment it operates in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which impedes the MAPK/ERK pathway. The MAPK/ERK pathway is involved in cell differentiation and proliferation. By inhibiting this pathway, PD98059 can indirectly affect HoxB13's role in these processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is an inhibitor of the TGF-β receptor. It prevents phosphorylation of SMAD proteins, thereby inhibiting TGF-β signaling. This signaling is vital for various cellular processes including development and differentiation, which are areas where HoxB13 plays a role. Inhibiting TGF-β signaling could thus indirectly impact HoxB13 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. The JNK pathway is involved in cellular stress responses and apoptosis. By modulating this pathway, SP600125 could indirectly impact HoxB13, which is implicated in cell developmental processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is involved in inflammatory responses and cell differentiation. By inhibiting this pathway, SB203580 could indirectly modify the activity of HoxB13. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT is a γ-secretase inhibitor, affecting Notch signaling. Notch signaling is crucial for cell fate decisions. By modulating this pathway, DAPT can influence cellular environments where HoxB13 is active. | ||||||
Bicalutamide | 90357-06-5 | sc-202976 sc-202976A | 100 mg 500 mg | $42.00 $146.00 | 27 | |
Bicalutamide is an androgen receptor antagonist. While primarily known for its role in hormone signaling, androgen signaling also intersects with various developmental pathways where HoxB13 is implicated. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a CDK4/6 inhibitor. By inhibiting these cyclin-dependent kinases, it affects cell cycle progression. HoxB13, involved in cell differentiation, could be indirectly influenced by changes in the cell cycle. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid is an HDAC inhibitor. It affects chromatin structure and gene expression. By altering gene expression patterns, Vorinostat could indirectly influence HoxB13 activity. | ||||||